Results of the use of trastuzumab combined with different chemotherapy regimens in first-line treatment of HER2-positive disseminated gastric cancer
Gastric cancer (GC) is one of the most common types of malignant tumour worldwide and is ranked fifth in the cancer incidence pattern and third in the cancer mortality pattern. In the Russian Federation, 39.9% of patients are diagnosed with stage IV gastric cancer, 46.6% of patients die within the f...
Main Authors: | N. S. Besova, T. A. Titova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2019-06-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/3062 |
Similar Items
-
Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01) -
Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
by: Tong G, et al.
Published: (2020-04-01) -
Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01) -
The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
by: Xinwei Wang, et al.
Published: (2022-07-01) -
HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment
by: N S Besova
Published: (2014-09-01)